- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03286881
Brief Evidence-based Psychological Treatments for Emotional Disorders (PsycBrief)
April 28, 2021 updated by: Jorge Corpas López, Universidad de Córdoba
Brief Evidence-based Psychological Treatments for Emotional Disorders. A Randomized Clinical Trial in Primary and Secondary Care.
The present work aims to develop a randomized clinical trial with a sample of 165 patients diagnosed with an emotional disorder.
All participants are tested by several self-reports related to common mental disorders in a repeated measures design, pre and post treatment as well as a six month follow up.
We think this study will demonstrate that brief psychological treatments should be prioritized over pharmacological treatment for such pathologies in the Primary or Secondary Care context to improve the patient´s quality of life while simultaneously reducing costs.
Study Overview
Status
Completed
Detailed Description
Nowadays, the heavy demands placed on health systems exceed the resources in many developed countries.
So-called "common mental disorders" and their mostly pharmacological treatment are, in no small part, responsible for this situation.
The cost that these disorders generate to the public health service is very high and they are usually associated with other issues like hyperfrequentation and side effects.
However, research indicates that psychological treatment should be the first step when caring for these types of problems.
We expect that the results show that extensive psychological therapy and combined treatment were the most effective.
Nevertheless, brief psychological treatment is expected to be the most efficient in cost-benefit terms.
Study Type
Interventional
Enrollment (Actual)
129
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Córdoba
-
Cordoba, Córdoba, Spain, 14071
- Universidad de Córdoba
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Emotional disorders
Exclusion Criteria:
- Severe mental disorder
- Drug abuse
- Severe depression
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 2
|
Group brief psychological intervention by adaptation of the Guide NICE "Common Mental Health Disorders" (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010).
This intervention is provided by clinical psychologist in primary care.
|
Experimental: Group 1
|
Individual brief psychological intervention by adaptation of the Guide NICE "Common Mental Health Disorders" (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010).
This intervention is provided by clinical psychologist in secondary care.
|
Experimental: Group 3
|
Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.
|
Experimental: Group 4
|
Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
|
Active Comparator: Group 5
|
Medication provided by a general practitioner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Generalised Anxiety Disorder Assessment (GAD-7)
Time Frame: 12 weeks
|
The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions.
Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
When used as a screening tool, further evaluation is recommended when the score is 10 or greater.
Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for GAD.
|
12 weeks
|
The Patient Health Questionnaire (PHQ-9)
Time Frame: 12 weeks
|
The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day).
|
12 weeks
|
Beck Depression Inventory-Second Edition (BDI-II)
Time Frame: 12 weeks
|
The BDI-II is a widely used 21-item self-report inventory measuring the severity of depression in adolescents and adults.
The BDI-II was revised in 1996 to be more consistent with DSM-IV criteria for depression.
For example, individuals are asked to respond to each question based on a two-week time period rather than the one-week timeframe on the BDI.
The BDI-II is widely used as an indicator of the severity of depression, but not as a diagnostic tool, and numerous studies provide evidence for its reliability and validity across different populations and cultural groups.
|
12 weeks
|
The State-Trait Anxiety Inventory (STAI)
Time Frame: 12 weeks
|
The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983).
It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes.
It also is often used in research as an indicator of caregiver distress AnxietyForm Y, its most popular version, has 20 items for assessing trait anxiety and 20 for state anxiety.
All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always").
Higher scores indicate greater anxiety.
The STAI is appropriate for those who have at least a sixth-grade reading level.
Internal consistency coefficients for the scale have ranged from .86 to .95;
test-retest reliability coefficients have ranged from .65 to .75 over a 2-month interval (Spielberger et al., 1983).
|
12 weeks
|
The Patient Health Questionnaire (PHQ-15)
Time Frame: 12 weeks
|
The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.The PHQ-15 is the somatization module, which scores each DSM-IV criteria as "0" (not bothered at all) to "2" (bothered a lot).
|
12 weeks
|
The Patient Health Questionnaire (PHQ-PD)
Time Frame: 12 weeks
|
The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.The PHQ-PD is the panic disorder module, which scores each DSM-IV criteria as "yes" or "no".
|
12 weeks
|
Brief Symptom Inventory 18 (BSI-18)
Time Frame: 12 weeks
|
The BSI-18 contains the three six-item scales somatization, depression, and anxiety as well as the Global Severity Index (GSI), including all 18 items.
The BSI-18 is the latest and shortest of the multidimensional versions of the Symptom-Checklist 90-R.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Juan Antonio Moriana E, Universidad de Córdoba
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2017
Primary Completion (Actual)
April 15, 2018
Study Completion (Actual)
January 15, 2021
Study Registration Dates
First Submitted
September 12, 2017
First Submitted That Met QC Criteria
September 14, 2017
First Posted (Actual)
September 19, 2017
Study Record Updates
Last Update Posted (Actual)
April 29, 2021
Last Update Submitted That Met QC Criteria
April 28, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PSI2014-56368-R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Brief individual psychotherapy
-
Randi UlbergUniversity of OsloCompleted
-
University of RochesterNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
The Royal Ottawa Mental Health CentreCompletedMajor Depressive Disorder
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityUnknown
-
University of GeorgiaHenry Ford Health SystemCompletedDepression | Migraine Disorders | Headaches ChronicUnited States
-
New York State Psychiatric InstituteNot yet recruitingDepression | PTSD | Anxiety | Intimate Partner Violence
-
University of OsloThe Research Council of NorwayCompletedPersonality Disorders | Mood Disorders | Anxiety DisordersNorway
-
University of North Carolina, Chapel HillUniversity of Pavia; European CommissionNot yet recruitingPsychotherapy | Psychological | Therapeutic AllianceUnited States
-
Weill Medical College of Cornell UniversityUnknownIdentity Pathology | Behavior ProblemsUnited States
-
US Department of Veterans AffairsCompletedHepatitis C | Stress Disorders, Post-Traumatic | Chronic DiseaseUnited States